Washington: A new study has identified an enzyme called Monoacylglycerol lipase (MAGL) as a potential therapeutic target to treat or prevent Alzheimer’s disease. The research team found that inactivation of MAGL, best known for its role in degrading a cannabinoid produced in the brain, reduced the production and accumulation of beta amyloid plaques, a pathological hallmark of Alzheimer’s disease. Inhibition of this enzyme also decreased neuroinflammation and neurodegeneration, and improved plasticity of the brain, learning and memory. "Our results suggest that MAGL contributes to the cause and development of Alzheimer’s disease and that blocking MAGL represents a promising therapeutic target," said lead researcher Dr. Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Canter New Orleans.
Now, a device that diagnoses cancer in just 20 minutes
Flu virus may trigger Diabetes